Assessment of Circulating Immune Cells as a Prognostic Factor in Patients With Advanced Hepatocellular Carcinoma Treated With Immunotherapy
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Liver cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms IMMUNOCELL
- 11 Sep 2023 Planned End Date changed from 30 Sep 2024 to 8 Sep 2027.
- 11 Sep 2023 Planned primary completion date changed from 30 Sep 2024 to 8 Sep 2025.
- 11 Sep 2023 Status changed from not yet recruiting to recruiting.